Bicara Therapeutics Inc.
BCAX
$26.87
$0.532.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.80M | 30.51M | 29.13M | 26.19M | 22.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.06M | 155.60M | 141.12M | 121.07M | 108.80M |
| Operating Income | -174.06M | -155.60M | -141.12M | -121.07M | -108.80M |
| Income Before Tax | -157.12M | -137.73M | -121.17M | -102.36M | -92.08M |
| Income Tax Expenses | 197.00K | 217.00K | 350.00K | 310.00K | 258.00K |
| Earnings from Continuing Operations | -157.32 | -137.95 | -121.52 | -102.67 | -92.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.32M | -137.95M | -121.52M | -102.67M | -92.33M |
| EBIT | -174.06M | -155.60M | -141.12M | -121.07M | -108.80M |
| EBITDA | -173.93M | -155.50M | -141.04M | -121.00M | -108.74M |
| EPS Basic | -2.77 | -2.52 | -2.23 | -3.17 | -21.68 |
| Normalized Basic EPS | -1.73 | -1.57 | -1.39 | -1.98 | -13.55 |
| EPS Diluted | -2.77 | -2.52 | -2.23 | -3.17 | -21.68 |
| Normalized Diluted EPS | -1.73 | -1.57 | -1.39 | -1.98 | -13.55 |
| Average Basic Shares Outstanding | 224.96M | 218.70M | 217.98M | 174.32M | 120.68M |
| Average Diluted Shares Outstanding | 224.96M | 218.70M | 217.98M | 174.32M | 120.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |